Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

034IC - Urinary Diversion – Current Indications, Techniques & Complications

Saturday, May 19
4:00 PM - 6:00 PM
Location: MCC WEST, 2008

This course will offer a detailed description of various forms of urinary diversions, including the ileal conduit, orthotopic neobladder, and a variety of continent cutaneous diversions. The discussion will specifically focus on the techniques of reconstruction, appropriate patient selection, and management of common complications with video presentation of the orthotopic ileal neobladder and a right colon pouch with appendico-umbilicostomy. Patient outcomes based on published literature and personal experience will be reviewed. We will also discuss management of complications encountered with various forms of diversion, with step-by-step instructions on techniques such as injection of bulking agents for stomal incontinence to management of pouch stones and pouch revision. This course is suited for the urologist who wishes to not only expand the repertoire of urinary diversions offered to adult and pediatric patients but also refine techniques of managing common complications. It will also be suited for nurse practitioners and physician’s assistants who care for patients undergoing urinary diversion.

Learning Objectives:

Siamak Daneshmand

University of Southern California

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of urologic oncology, director of clinical research as well as the urologic oncology (SUO) fellowship director.
Dr. Daneshmand’s main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion. He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on non-muscle invasive bladder cancer as well as testicular cancer. He is a member of Alpha Omega Alpha medical honor society, and has been designated one of the “America’s Top Cancer Doctors” for the past 9 consecutive years. He has presented over 300 abstracts at scientific meetings and has authored over 200 peer-reviewed articles, reviews, and book chapters.

Presentation(s):

Send Email for Siamak Daneshmand

Eila C. Skinner

Department of Urology, Stanford University

Dr. Skinner is the Chair of the Department of Urology at Stanford University and the Thomas A. Stamey Research Professor of Urology. She obtained her urologic training at Los Angeles County Hospital/USC School of Medicine and completed a fellowship in urologic oncology at USC Norris Comprehensive Cancer Center. She was on the faculty at Keck USC School of Medicine from 1990 through 2012 when she was recruited to Stanford.
Dr. Skinner’s research and clinical practice are focused on understanding the natural history of bladder cancer and refining treatments for high-risk non-muscle invasive and invasive bladder cancer, along with urinary tract reconstruction and continent urinary diversion. She was a member of the AUA Guidelines Committees on non-muscle invasive bladder cancer in 2008 and 2016 and is a trustee of the American Board of Urology.

Presentation(s):

Send Email for Eila Skinner


Assets

034IC - Urinary Diversion – Current Indications, Techniques & Complications

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Urinary Diversion – Current Indications, Techniques & Complications